Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma
Early weight loss ≥5% occurred in one fifth of patients receiving 1L EV+P treatment and was associated with inferior overall survival.
Authors
- Ryan D. Chow (ORCID: https://orcid.org/0000-0002-1872-6307)
- Ronac Mamtani (ORCID: https://orcid.org/0000-0002-8267-5356)
Institutions
- Penn Center for AIDS Research (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.clgc.2025.102417
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00